BIRC5 and urinary bladder carcinoma: Negative design lessons emerge in bladder cancer, where survivin siRNA plus paclitaxel lacked synergy due to survivin-induced cell-cycle arrest antagonizing taxanes, underscoring schedule/biology-aware co-delivery [66].